Camargo Hires Elaine Taylor, Director Of Research Services
Camargo Pharmaceutical Services is pleased to announce the new Director of Research Services, Elaine Taylor. Taylor will perform all scientific research writing activities and provide full life cycle support from clinical study protocols through regulatory submission and post approval activities. Taylor will ensure regulatory agencies and clients receive high quality IND's, NDA's, ANDA's and other applications related to all phases of the clients' drug development programs.
Taylor joins Camargo with over 20 years of experience in the pharmaceutical industry and research expertise in analytical chemistry, products research, pharmacology, toxicology and clinical studies (Phase I-IV). Her extensive background also includes a thorough understanding of regulatory affairs and requirements of the FDA, European and Canadian authorities.
"Elaine's expertise is sure to make a measurable impact on Camargo and the services we provide our clients. She has been focused on the preparation of regulatory documents in the medical industry for several years at very reputable companies. Our growing list of national and international clientele will benefit from her strategic knowledge and ability to effectively produce clear, concise documents for regulatory submission. I am confident that she will be a leader at Camargo," stated Camargo President and CEO, Ken Phelps.
Prior to joining Camargo, Taylor held numerous positions at Proctor & Gamble; most recently as the senior medical writer with responsibilities of preparing and writing a variety of documents for Phase I-IV clinical studies. Taylor earned her Bachelor of Science degree at Elmhurst College in Illinois.
About Camargo Pharmaceutical Services
Camargo Pharmaceutical Services is a full-service CRO for the continuum of drug development. With more than 150 FDA approvals, Camargo works with companies to develop comprehensive programs, managing every facet of the plan from formulation and testing the drug product, conducting clinical studies and FDA application submissions. For information Visit: www.camargopharma.com
SOURCE: Camargo Pharmaceutical Services